A recent study of how medical facilities in three countries meet minimum care standards for patients with childhood-onset systemic lupus erythematosus found a wide variation in quality of care…
In a recent review, researchers addressed skin injury in patients with SLE, discussing the effects of ultraviolet rays on the skin and the subsequent generation of autoantibodies. They concluded that UV rays activate immune cells where IgG has been deposited, resulting in inflammation…
Two Phase 3 trials have shown that epratuzumab did not meet its primary endpoints for treating SLE. Meanwhile, a Phase 3 study has shown adalimumab is effective for treating enthesitis-related arthritis in juveniles…
Phase 2 clinical trials have begun to assess the safety of brentuximab vedotin for the treatment of SLE. Also, the FDA is reviewing an application for a once-daily tofacitinib citrate tablet to treat RA…
From 1996–2011, the rates of hospitalization due to serious infectious diseases in patients with systemic lupus erythematosus (SLE) increased substantially, according to new research. In a retrospective data-driven study, researchers plotted and compared hospitalization and in-hospital mortality rates of SLE and non-SLE populations, determining the trends for the five most common infections…
Important new findings show that a majority of women with inactive or stable SLE can have successful pregnancies without experiencing flares and give birth to infants who survive the neonatal period…
In a Phase 2 study, researchers found that rontalizumab was a more effective treatment in patients with systemic lupus erythematosus who had an interferon signature metric score lower than 1.